Assessing the Effect of Nicotine Reduction on ENDS User's Addiction and Exposures
1 other identifier
interventional
116
1 country
1
Brief Summary
The rapid increase of electronic nicotine delivery systems (ENDS) use by young people in the US and their potential to harm health, cause addiction, and serve as a risk for cigarette smoking or dual-use is alarming. The epidemic of ENDS use among young people in the US has been associated with the rise in popularity of ENDS products that are very efficient in delivering high doses of nicotine to users. Therefore, the investigators propose to study the effects of nicotine reduction (NR) on young ENDS users as a potential regulatory strategy to reduce the addictiveness and use of ENDS. The proposed studies are directly responsive to research priories identified by the FDA and specified in this RFA under Addiction; studying the "Impact of changes in tobacco product characteristics (e.g. nicotine formulation) on dependence". This project aims to provide an overview of this project's rationale significance divided into 1) scientific rationale and regulatory implications; 2) the need to respond to the rising trend of ENDS use among young people in the US; 3) the importance of reducing the addictiveness of ENDS; 4) the strength of our clinical and analytical lab approach for regulatory purposes; and 5) the strengths and weaknesses in the rigor of prior research about NR for ENDS.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2022
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 15, 2021
CompletedFirst Posted
Study publicly available on registry
January 25, 2022
CompletedStudy Start
First participant enrolled
April 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 15, 2025
CompletedSeptember 23, 2025
September 1, 2025
3 years
December 15, 2021
September 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Plasma nicotine
Change in plasma nicotine level.
During the 2 participant visits. Blood will be taken 2 times in each electronic cigarette use session: before and after an approximately 60 minutes ad lib use period
Secondary Outcomes (9)
Minnesota Nicotine Withdrawal Scale
During participants' 2 study visits. Questionnaire will be administered 2 times in each electronic cigarette use session: before and after an approximately 60 minutes ad lib use period
Tiffany-Drobes Questionnaire of Smoking Urges
During participants' 2 study visits. Questionnaire will be administered 2 times in each electronic cigarette use session: before and after an approximately 60 minutes ad lib use period
Carbon monoxide levels
During participants' 2 study visits. Carbon monoxide levels will be measured 2 times in each electronic cigarette use session: before and after an approximately 60 minutes ad lib use period
Harm perception
During participants' 2 study visits. Questionnaire will be administered after each of the 2 electronic cigarette use sessions. Each session is approximately 60 minutes ad lib use period
Duke Sensory Questionnaire
During participants' 2 study visits. Questionnaire will be administered after each of the 2 electronic cigarette use sessions. Each session is approximately 60 minutes ad lib use period
- +4 more secondary outcomes
Other Outcomes (2)
Heart rate
During participants' 2 study visits. Heat rate will be measured from baseline continuously throughout each approximately 60 minutes session
Blood pressure
During participants' 2 study visits. Blood pressure will be measured from baseline continuously throughout each approximately 60 minutes session
Study Arms (3)
Electronic cigarette pods (SREC or NJOY) with 5% nicotine concentration
EXPERIMENTALParticipants will complete a lab visit where they will use 5% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
Electronic cigarette pods (NJOY) with 3% nicotine concentration
EXPERIMENTALParticipants will complete a lab visit where they will use 3% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
Electronic cigarette pods (SREC) with 0% nicotine concentration
EXPERIMENTALParticipants will complete a lab visit where they will use 0% nicotine electronic cigarette pods ad libitum for up to 60 minutes.
Interventions
Effects of e-cigarette pods (JUUL/NJOY/SREC) with 5% nicotine concentration nicotine concentration
Effects of e-cigarette pods (JUUL/NJOY) with 3% nicotine concentration
Effects of e-cigarette pods (SREC) with 0% nicotine concentration
Eligibility Criteria
You may qualify if:
- Generally healthy individuals (determined by physical examination).
- Age of 21-35 years.
- Is willing to provide informed consent.
- Is willing to attend the lab as required by the study protocol.
- Electronic cigarette users (defined as using electronic cigarette either daily or occasionally in the past 30 days)
- Have abstained from electronic cigarette use for 12 hours prior to each session
You may not qualify if:
- Report smoking cigarettes regularly (\> 5 cigarettes/month in the past year).
- Report regular use of any other tobacco/nicotine product (e.g.,hookah, pipes, cigars) in the past year.
- Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).
- Individuals with self-reported history of chronic disease or current psychiatric conditions.
- Individuals with history of or active cardiovascular disease, low or high blood pressure, seizures, and regular use of prescription medications (other than vitamins or birth control).
- Individuals that report current THC (marijuana) smoking/vaping.
- Individuals that report the use of non-commercial (i.e., street) e-cigarette liquid or products
- Individuals that report current EVALI or COVID-19 related symptoms (i.e., cough, shortness of breath, chest pain, nausea, vomiting, abdominal pain, diarrhea, fever, chills, or weight loss)
- Individuals that have or have been exposed to COVID-19 in the last 14 days.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Florida International University
Miami, Florida, 33199, United States
Related Publications (1)
Ferdous T, Roy S, Chowdhury S, Jebai R, Maya L, DeCaprio AP, Bursac Z, Maziak W. Partial Nicotine Reduction and E-Cigarette Users' Puffing Behaviors Among Adults Aged 21 to 35 Years: A Randomized Crossover Clinical Trial. JAMA Netw Open. 2024 Jul 1;7(7):e2422954. doi: 10.1001/jamanetworkopen.2024.22954.
PMID: 39058490DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wasim Maziak, PhD, MD
Florida International University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 15, 2021
First Posted
January 25, 2022
Study Start
April 1, 2022
Primary Completion
April 15, 2025
Study Completion
April 15, 2025
Last Updated
September 23, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share